Skip to content
Research Article Open access CC BY 4.0

Organotherapic Medicine Improves Blood Glucose Levels in AIDS Patients

A. R. T. Pupulin, L. Mortean, M. Spack Jr

Journal of Advances in Medicine and Medical Research · pp. 335–341 · Published 15 Dec 2014

10.9734/BJMMR/2015/14036

Abstract

Aims: To evaluate the effect of an organotherapic drug, produced from the pancreas of a young pig, on glycemic alterations in AIDS patients. Methodology: Current study was carried out in a double-blind, placebo controlled and randomized design. AIDS patients who had high fasting glucose (>110 mg/dL) were selected so that the effect of the organotherapic drug could be evaluated. The patients were divided into two groups: Group I comprised patients who received the organotherapic drug diluted in 1x1012 alcohol/ water 8%, once a day, with a sublingual-administered fasting dose of 10 drops, during four months. Group II consisted of patients receiving placebo once a day at the same dosage. Glucose oxidase method and ELISA, following the manufacturer’s instructions, respectively determined levels of glucose and insulin before treatment and monthly until four months after the start of treatment. Results: Results registered hyperglycemia in 30% of the patients (60/200), higher than in the population at large (7-15%). This fact could be related to the time of infection (10.0±4.78 years) and treatment (9.3±3.76 years) of the patients. On the other hand, patients who underwent treatment with organotherapic medicine showed a significant reduction (p<0,001) in blood glucose levels (from 204.5±86.63 to 86.63±16) and lower insulin levels after four months of treatment (organotherapic group with 8.02±3.598 versus placebo with 23.83±3.670 p<0,001) within normality, regardless of age, time of infection and time of treatment. This fact suggests that the organotherapic drug was effective to stabilize blood glucose levels in patients. Conclusion: Current study evidences that the organotherapic drug obtained from the pancreas of a young pig, diluted 1x1012 in alcohol/ water 8% improves blood glucose levels in patients with hyperglycemia keeping within the normal range after four months of treatment. Considering the HAART therapy that significantly increases the life expectancy of AIDS patients but with significant metabolic alterations this study shows the possibility of utilization of complementary and alternative therapies. Although results indicate a significant effect of the organotherapic drug, additional studies are needed to evaluate the long-term effects.

Organotherapic medicine HIV/AIDS blood glucose insulin level complications

References (23)

  1. 1 Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection [DOI]
  2. 2 Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease [DOI]
  3. 3 Coronary Heart Disease in HIV-Infected Individuals [DOI]
  4. 4 Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients [DOI]
  5. 5 Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study [DOI]
  6. 6 Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment [DOI]
  7. 7 Understanding diabetes in patients with HIV/AIDS [DOI]
  8. 8 Exposure to Nanoparticles and Hormesis [DOI]
  9. 9 Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected and HIV-Uninfected Women in the Women's Interagency HIV Study [DOI]
  10. 10 Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study [DOI]
  11. 11 Predicting the short‐term risk of diabetes in HIV‐positive patients: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study [DOI]
  12. 12 Coronary Heart Disease in HIV-Infected Individuals [DOI]
  13. 13 Autoimmune Diabetes in HIV-Infected Patients on Highly Active Antiretroviral Therapy [DOI]
  14. 14 Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China [DOI]
  15. 15 HIV and HIV treatment: effects on fats, glucose and lipids [DOI]
  16. 16 Disorders of glucose metabolism in the context of human immunodeficiency virus infection [DOI]
  17. 17 Cell Therapy for Diabetes Mellitus: An Opportunity for Stem Cells? [DOI]
  18. 18 Lipodystrophy Syndrome: The Morphologic and Metabolic Effects of Antiretroviral Therapy in HIV Infection [DOI]
  19. 19 Defining the Metabolic Syndrome Construct [DOI]
  20. 20 [AIDS - an old disease with new challenges].
  21. 21 A Brief Definition of Regenerative Medicine [DOI]
  22. 22 HIV Therapy and Diabetes Risk [DOI]
  23. 23 Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care.

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

59

Page views

0

PDF downloads

40

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.